ketoconazole has been researched along with Innate Inflammatory Response in 10 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Endogenous TRPV1 agonists such as oxidized linoleic acid metabolites (OLAMs) and the enzymes releasing them [eg, cytochrome P450 (CYP)] are up-regulated after inflammation in the rat." | 7.79 | Oxidized linoleic acid metabolite-cytochrome P450 system (OLAM-CYP) is active in biopsy samples from patients with inflammatory dental pain. ( de Almeida, JFA; Eskander, M; Hargreaves, KM; Henry, MA; Roman, L; Rowan, S; Ruparel, S, 2013) |
| "Pretreatment with ketoconazole inhibited the release of TRPV1 agonists in lipid extracts from inflamed skin and significantly reversed CFA-induced heat hyperalgesia by a peripheral mechanism of action." | 5.38 | The cytochrome P450 inhibitor, ketoconazole, inhibits oxidized linoleic acid metabolite-mediated peripheral inflammatory pain. ( Chen, P; Green, D; Hargreaves, KM; Ruparel, S, 2012) |
| "Endogenous TRPV1 agonists such as oxidized linoleic acid metabolites (OLAMs) and the enzymes releasing them [eg, cytochrome P450 (CYP)] are up-regulated after inflammation in the rat." | 3.79 | Oxidized linoleic acid metabolite-cytochrome P450 system (OLAM-CYP) is active in biopsy samples from patients with inflammatory dental pain. ( de Almeida, JFA; Eskander, M; Hargreaves, KM; Henry, MA; Roman, L; Rowan, S; Ruparel, S, 2013) |
| "Indomethacin is a known immune modulator that inhibits cyclooxygenase." | 2.73 | Pharmacological prevention of the deleterious effects of cardiopulmonary bypass. ( Afrakhteh, M; Givtaj, N; Hassantash, SA; Omrani, GR, 2007) |
| "Keratitis is a major cause of avoidable visual impairment." | 1.46 | Condition responsive nanoparticles for managing infection and inflammation in keratitis. ( Ahsan, SM; Rao, CM, 2017) |
| "Cholestasis is one of the major causes of drug-induced liver injury (DILI), which can result in withdrawal of approved drugs from the market." | 1.46 | Mechanism-based risk assessment strategy for drug-induced cholestasis using the transcriptional benchmark dose derived by toxicogenomics. ( Honda, H; Ito, Y; Kawamoto, T; Morita, O, 2017) |
| "Pretreatment with ketoconazole inhibited the release of TRPV1 agonists in lipid extracts from inflamed skin and significantly reversed CFA-induced heat hyperalgesia by a peripheral mechanism of action." | 1.38 | The cytochrome P450 inhibitor, ketoconazole, inhibits oxidized linoleic acid metabolite-mediated peripheral inflammatory pain. ( Chen, P; Green, D; Hargreaves, KM; Ruparel, S, 2012) |
| "P-glycoprotein is an efflux pump belonging to the ATP-binding cassette super-family that influences the bioavailability and disposition of many drugs." | 1.36 | Tumor necrosis factor alpha increases P-glycoprotein expression in a BME-UV in vitro model of mammary epithelial cells. ( Al-Bataineh, MM; Gehring, R; Schultz, BD; van der Merwe, D, 2010) |
| "It constitutes a new alternative in the treatment of facial seborrheic dermatitis, regardless of severity." | 1.34 | [Lithium gluconate 8% in the treatment of seborrheic dermatitis]. ( Blouin, E; Dréno, B; Moyse, D, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amir, M | 1 |
| Kumar, H | 1 |
| Javed, SA | 1 |
| Ahsan, SM | 1 |
| Rao, CM | 1 |
| Kawamoto, T | 1 |
| Ito, Y | 1 |
| Morita, O | 1 |
| Honda, H | 1 |
| Ruparel, S | 2 |
| Hargreaves, KM | 2 |
| Eskander, M | 1 |
| Rowan, S | 1 |
| de Almeida, JFA | 1 |
| Roman, L | 1 |
| Henry, MA | 1 |
| Esposito, G | 1 |
| Gigli, S | 1 |
| Seguella, L | 1 |
| Nobile, N | 1 |
| D'Alessandro, A | 1 |
| Pesce, M | 1 |
| Capoccia, E | 1 |
| Steardo, L | 1 |
| Cirillo, C | 1 |
| Cuomo, R | 1 |
| Sarnelli, G | 1 |
| Al-Bataineh, MM | 1 |
| van der Merwe, D | 1 |
| Schultz, BD | 1 |
| Gehring, R | 1 |
| Jeschke, MG | 1 |
| Williams, FN | 1 |
| Finnerty, CC | 1 |
| Rodriguez, NA | 1 |
| Kulp, GA | 1 |
| Ferrando, A | 1 |
| Norbury, WB | 1 |
| Suman, OE | 1 |
| Kraft, R | 1 |
| Branski, LK | 1 |
| Al-mousawi, AM | 1 |
| Herndon, DN | 1 |
| Green, D | 1 |
| Chen, P | 1 |
| Dréno, B | 1 |
| Blouin, E | 1 |
| Moyse, D | 1 |
| Hassantash, SA | 1 |
| Omrani, GR | 1 |
| Givtaj, N | 1 |
| Afrakhteh, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of the Treatment of the Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation[NCT00675714] | Phase 2/Phase 3 | 1,126 participants (Actual) | Interventional | 2004-01-31 | Terminated (stopped due to At the request of the study site, this study has been closed and access to study-related data is unavailable. We are unable to submit the results-data.) | ||
| Assessment of Mechanisms of Improved Wound Healing of Anabolic Agents and Diet in Severely Burned Patients[NCT00673309] | Phase 2/Phase 3 | 644 participants (Actual) | Interventional | 2000-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for ketoconazole and Innate Inflammatory Response
| Article | Year |
|---|---|
The effect of ketoconazole on post-burn inflammation, hypermetabolism and clinical outcomes.
Topics: 14-alpha Demethylase Inhibitors; Acute-Phase Proteins; Antifungal Agents; Body Composition; Burns; C | 2012 |
The effect of ketoconazole on post-burn inflammation, hypermetabolism and clinical outcomes.
Topics: 14-alpha Demethylase Inhibitors; Acute-Phase Proteins; Antifungal Agents; Body Composition; Burns; C | 2012 |
The effect of ketoconazole on post-burn inflammation, hypermetabolism and clinical outcomes.
Topics: 14-alpha Demethylase Inhibitors; Acute-Phase Proteins; Antifungal Agents; Body Composition; Burns; C | 2012 |
The effect of ketoconazole on post-burn inflammation, hypermetabolism and clinical outcomes.
Topics: 14-alpha Demethylase Inhibitors; Acute-Phase Proteins; Antifungal Agents; Body Composition; Burns; C | 2012 |
Pharmacological prevention of the deleterious effects of cardiopulmonary bypass.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Coagulation; C-Reactive Protein; Cardiac Surgical Pro | 2007 |
8 other studies available for ketoconazole and Innate Inflammatory Response
| Article | Year |
|---|---|
Condensed bridgehead nitrogen heterocyclic system: synthesis and pharmacological activities of 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole derivatives of ibuprofen and biphenyl-4-yloxy acetic acid.
Topics: Acute Disease; Analgesics; Animals; Bacteria; Diphenylacetic Acids; Female; Fungi; Hepatocytes; Ibup | 2008 |
Condition responsive nanoparticles for managing infection and inflammation in keratitis.
Topics: Animals; Antibodies; Antifungal Agents; Cells, Cultured; Cornea; Drug Delivery Systems; Eye Infectio | 2017 |
Mechanism-based risk assessment strategy for drug-induced cholestasis using the transcriptional benchmark dose derived by toxicogenomics.
Topics: Administration, Oral; Animals; Chlorpromazine; Cholestasis; Cholesterol; Cyclosporine; Diclofenac; D | 2017 |
Oxidized linoleic acid metabolite-cytochrome P450 system (OLAM-CYP) is active in biopsy samples from patients with inflammatory dental pain.
Topics: Animals; Biopsy; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme Inhibitors; Cytochrom | 2013 |
Rifaximin, a non-absorbable antibiotic, inhibits the release of pro-angiogenic mediators in colon cancer cells through a pregnane X receptor-dependent pathway.
Topics: Anti-Bacterial Agents; Caco-2 Cells; Cell Movement; Cell Proliferation; Colonic Neoplasms; Gene Expr | 2016 |
Tumor necrosis factor alpha increases P-glycoprotein expression in a BME-UV in vitro model of mammary epithelial cells.
Topics: 14-alpha Demethylase Inhibitors; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; A | 2010 |
The cytochrome P450 inhibitor, ketoconazole, inhibits oxidized linoleic acid metabolite-mediated peripheral inflammatory pain.
Topics: Animals; Antibodies; Behavior, Animal; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme S | 2012 |
[Lithium gluconate 8% in the treatment of seborrheic dermatitis].
Topics: Administration, Topical; Dermatitis, Seborrheic; Gluconates; Humans; Inflammation; Ketoconazole; Lit | 2007 |